Key result
Evolocumab is linked to probable immune-mediated hemorrhagic pericarditis and cardiac tamponade in a case report.
Why the study?
Pericardial disease associated with PCSK9 inhibitors is extremely rare, though immune-mediated inflammatory reactions may occur with monoclonal antibodies.
Case Report (n=1)
Evolocumab may be associated with rare but severe immune-mediated hemorrhagic pericarditis and cardiac tamponade, requiring clinical vigilance.
Answers are grounded in this paper and cite their sources.
Warrants vigilance for tamponade on evolocumab; single case leaves open causality.
Background Evolocumab, a fully humanized monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), is one of the most widely used lipid-lowering therapies for atherosclerotic cardiovascular disease (ASCVD). It is generally well-tolerated, but immune-mediated inflammatory reactions may occur with monoclonal antibodies. Among common adverse effects associated with evolocumab, pericardial disease associated with PCSK9 inhibitors is extremely rare. Case Presentation A man in the late 70s on evolocumab for two months presented to the hospital for atrial flutter and moderate pericardial effusion. He was treated with amiodarone and discharged with colchicine and indomethacin. Ten days later, the patient represented with worsening shortness of breath, malaise, and jugular venous distension with echocardiographic evidence of tamponade physiology. Emergent pericardiocentesis drained about one liter of sanguineous fluid. Autoimmune, infectious, and malignant etiologies were systematically excluded. Evolocumab was discontinued, and the patient remained asymptomatic without recurrence. Discussion This case illustrates a probable immune-mediated pericarditis with hemorrhagic effusion and tamponade seen with evolocumab use. Clinicians should remain vigilant for this rare monoclonal antibody–associated pericardial inflammation as a potentially serious adverse reaction to evolocumab, particularly when other common causes have been excluded. Continued pharmacovigilance is essential as the use of PCSK9 inhibitors expands.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a case report in Hemorrhagic pericarditis with cardiac tamponade (n=1). Evolocumab was evaluated on Hemorrhagic pericarditis with cardiac tamponade. Evolocumab use was associated with probable immune-mediated hemorrhagic pericarditis and cardiac tamponade in a man in his late 70s, which resolved after drug discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: